Literature DB >> 27956549

Loss of Glyoxalase 1 Induces Compensatory Mechanism to Achieve Dicarbonyl Detoxification in Mammalian Schwann Cells.

Jakob Morgenstern1, Thomas Fleming2, Dagmar Schumacher3, Volker Eckstein4, Marc Freichel3, Stephan Herzig5, Peter Nawroth6.   

Abstract

The glyoxalase system is a highly specific enzyme system existing in all mammalian cells that is responsible for the detoxification of dicarbonyl species, primarily methylglyoxal (MG). It has been implicated to play an essential role in preventing the increased formation of advanced glycation end products under certain pathological conditions. We have established the first glyoxalase 1 knock-out model (GLO1-/-) in mammalian Schwann cells using the CRISPR/Cas9 technique to investigate compensatory mechanisms. Neither elevated concentrations of MG nor associated protein modifications were observed in GLO1-/- cells. Alternative detoxification of MG in GLO1-/- is achieved by increased catalytic efficiency of aldose reductase toward hemithioacetal (product of glutathione and MG), which is most likely caused by S-nitrosylation of aldose reductase. The hemithioacetal is mainly converted into lactaldehyde, which is paralleled by a loss of reduced glutathione. Inhibition of aldose reductase in GLO1-/- cells is associated with an increased sensitivity against MG, elevated intracellular MG levels, associated modifications, as well as increased oxidative stress. Our data suggest that aldose reductase can compensate for the loss of GLO1. This might be of clinical importance within the context of neuronal diseases caused by an impaired glyoxalase system and elevated levels of dicarbonyl species, such as MG.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  CRISPR/Cas; aldose reductase; cell metabolism; diabetes; diabetic neuropathy; enzyme kinetics; glycation; glyoxalase system; methylglyoxal; toxicity

Mesh:

Substances:

Year:  2016        PMID: 27956549      PMCID: PMC5336158          DOI: 10.1074/jbc.M116.760132

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

Review 1.  Clinical review: The role of advanced glycation end products in progression and complications of diabetes.

Authors:  Su-Yen Goh; Mark E Cooper
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

Review 2.  Mechanisms of diabetic neuropathy: Schwann cells.

Authors:  Andrew P Mizisin
Journal:  Handb Clin Neurol       Date:  2014

3.  Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose.

Authors:  P J Thornalley; A Langborg; H S Minhas
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

4.  Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil.

Authors:  S A Phillips; D Mirrlees; P J Thornalley
Journal:  Biochem Pharmacol       Date:  1993-09-01       Impact factor: 5.858

5.  Nitric oxide generation from streptozotocin.

Authors:  N S Kwon; S H Lee; C S Choi; T Kho; H S Lee
Journal:  FASEB J       Date:  1994-05       Impact factor: 5.191

6.  Glyoxalase activity in human red blood cells fractioned by age.

Authors:  A C McLellan; P J Thornalley
Journal:  Mech Ageing Dev       Date:  1989-04       Impact factor: 5.432

7.  Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry.

Authors:  Paul J Thornalley; Sinan Battah; Naila Ahmed; Nikolaos Karachalias; Stamatina Agalou; Roya Babaei-Jadidi; Anne Dawnay
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

8.  Proteomic quantification and site-mapping of S-nitrosylated proteins using isobaric iodoTMT reagents.

Authors:  Zhe Qu; Fanjun Meng; Ryan D Bomgarden; Rosa I Viner; Jilong Li; John C Rogers; Jianlin Cheng; C Michael Greenlief; Jiankun Cui; Dennis B Lubahn; Grace Y Sun; Zezong Gu
Journal:  J Proteome Res       Date:  2014-06-13       Impact factor: 4.466

9.  Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples.

Authors:  Naila Rabbani; Paul J Thornalley
Journal:  Nat Protoc       Date:  2014-07-24       Impact factor: 13.491

10.  Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice.

Authors:  Ferdinando Giacco; Xueliang Du; Vivette D D'Agati; Ross Milne; Guangzhi Sui; Michele Geoffrion; Michael Brownlee
Journal:  Diabetes       Date:  2013-09-23       Impact factor: 9.461

View more
  17 in total

1.  Discovery and Optimization of Inhibitors of the Parkinson's Disease Associated Protein DJ-1.

Authors:  Shinya Tashiro; Jose M M Caaveiro; Makoto Nakakido; Aki Tanabe; Satoru Nagatoishi; Yasushi Tamura; Noriyuki Matsuda; Dali Liu; Quyen Q Hoang; Kouhei Tsumoto
Journal:  ACS Chem Biol       Date:  2018-08-15       Impact factor: 5.100

2.  The combination of loss of glyoxalase1 and obesity results in hyperglycemia.

Authors:  Elisabeth Lodd; Lucas M Wiggenhauser; Jakob Morgenstern; Thomas H Fleming; Gernot Poschet; Michael Büttner; Christoph T Tabler; David P Wohlfart; Peter P Nawroth; Jens Kroll
Journal:  JCI Insight       Date:  2019-06-20

Review 3.  Methylglyoxal and Its Adducts: Induction, Repair, and Association with Disease.

Authors:  Seigmund Wai Tsuen Lai; Edwin De Jesus Lopez Gonzalez; Tala Zoukari; Priscilla Ki; Sarah C Shuck
Journal:  Chem Res Toxicol       Date:  2022-10-05       Impact factor: 3.973

4.  Combined glyoxalase 1 dysfunction and vitamin B6 deficiency in a schizophrenia model system causes mitochondrial dysfunction in the prefrontal cortex.

Authors:  Kazuya Toriumi; Stefano Berto; Shin Koike; Noriyoshi Usui; Takashi Dan; Kazuhiro Suzuki; Mitsuhiro Miyashita; Yasue Horiuchi; Akane Yoshikawa; Mai Asakura; Kenichiro Nagahama; Hsiao-Chun Lin; Yuki Sugaya; Takaki Watanabe; Masanobu Kano; Yuki Ogasawara; Toshio Miyata; Masanari Itokawa; Genevieve Konopka; Makoto Arai
Journal:  Redox Biol       Date:  2021-06-24       Impact factor: 11.799

5.  Hormetic potential of methylglyoxal, a side-product of glycolysis, in switching tumours from growth to death.

Authors:  Marie-Julie Nokin; Florence Durieux; Justine Bellier; Olivier Peulen; Koji Uchida; David A Spiegel; James R Cochrane; Craig A Hutton; Vincent Castronovo; Akeila Bellahcène
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

Review 6.  Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention.

Authors:  Sebastian Brings; Thomas Fleming; Marc Freichel; Martina U Muckenthaler; Stephan Herzig; Peter P Nawroth
Journal:  Int J Mol Sci       Date:  2017-05-05       Impact factor: 5.923

7.  Hormesis enables cells to handle accumulating toxic metabolites during increased energy flux.

Authors:  Johanna Zemva; Christoph Andreas Fink; Thomas Henry Fleming; Leonard Schmidt; Anne Loft; Stephan Herzig; Robert André Knieß; Matthias Mayer; Bernd Bukau; Peter Paul Nawroth; Jens Tyedmers
Journal:  Redox Biol       Date:  2017-08-12       Impact factor: 11.799

Review 8.  The Glyoxalase System and Methylglyoxal-Derived Carbonyl Stress in Sepsis: Glycotoxic Aspects of Sepsis Pathophysiology.

Authors:  Thomas Schmoch; Florian Uhle; Benedikt H Siegler; Thomas Fleming; Jakob Morgenstern; Peter P Nawroth; Markus A Weigand; Thorsten Brenner
Journal:  Int J Mol Sci       Date:  2017-03-17       Impact factor: 5.923

9.  Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma.

Authors:  Maurice Michel; Marcus Hollenbach; Sabine Pohl; Cristina Ripoll; Alexander Zipprich
Journal:  Front Oncol       Date:  2019-08-20       Impact factor: 6.244

10.  Compensatory mechanisms for methylglyoxal detoxification in experimental & clinical diabetes.

Authors:  Dagmar Schumacher; Jakob Morgenstern; Yoko Oguchi; Nadine Volk; Stefan Kopf; Jan Benedikt Groener; Peter Paul Nawroth; Thomas Fleming; Marc Freichel
Journal:  Mol Metab       Date:  2018-09-19       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.